A PHASE 2, OPEN-LABEL, PROSPECTIVE STUDY OF PRM-151 IN SUBJECTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MF (POST-PV MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MF (POST-ET MF)

Registry ID

PRM-151G-101

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

HOFFMANN-LA ROCHE LIMITED

Start date

2013-10-08

Completion date

2020-07-10

Last update

2013-07-19

Conditions

• THROMBOCYTHEMIA MYELOFIBROSIS
• POLYCYTHEMIA VERA (PV)
• PRIMARY MYELOFIBROSIS (PMF)

Related clinical trials

• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER PHASE 3 CLINICAL STUDY TO ASSESS EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B (P1101) IN ADULT PATIENTS WITH PRE-FIBROTIC/EARLY PRIMARY MYELOFIBROSIS OR OVERT PRIMARY MYELOFIBROSIS AT LOW OR INTERMEDIATE-1 RISK ACCORDING TO DIPSS PLUS (HOPEPMF): THE CORE STUDY AND ITS EXTENSION STUDY
• AN OPEN LABEL, MULTI-CENTER, PHASE IV ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR GLOBAL NOVARTIS OR INCYTE SPONSORED RUXOLITINIB (INC424) STUDY OR A STUDY OF RUXOLITINIB IN COMBINATION EITHER WITH PANOBINOSTAT (LBH589) OR SIREMADLIN (HDM201) OR RINETERKIB (LTT462), AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT
• A PHASE IIIB, SINGLE-ARM, MULTICENTER STUDY TO ACCESS EFFICACY, SAFETY, AND TOLERABILITY OF ROPEGINTERFERON ALFA-2B-NJFT (P1101) IN ADULT PATIENTS WITH POLYCYTHEMIA VERA (PV)
• A PHASE 3 STUDY OF THE HEPCIDIN MIMETIC RUSFERTIDE (PTG-300) IN PATIENTS WITH POLYCYTHEMIA VERA
• A RANDOMIZED, CONTROLLED PHASE 3 STUDY OF PACRITINIB VERSUS PHYSICIAN'S CHOICE IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA (PLATELETS COUNTS <50,000/MCL)
• A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE ACTIVITY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) IN SYMPTOMATIC, ANEMIC SUBJECTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA (PV) MYELOFIBROSIS, OR POST ESSENTIAL THROMBOCYTHEMIA (ET) MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH JAK INHIBITOR THERAPY

View on source registry